Home
/
Esperion Therapeutics, Inc.
/
Financials
/
Quarterly
Esperion Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Esperion Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$87.31M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$82.39M
Aug 13, 2025
Q1
2025
Mar 31, 2025
$65.00M
May 8, 2025
Q3
2025
Sep 30, 2024
$51.63M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$73.83M
Aug 13, 2025
Q1
2025
Mar 31, 2024
$137.74M
May 8, 2025
Q3
2024
Sep 30, 2023
$33.97M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$25.79M
Aug 12, 2024
Q1
2024
Mar 31, 2023
$24.33M
May 7, 2024
Q3
2023
Sep 30, 2022
$18.98M
Nov 7, 2023
Q2
2023
Jun 30, 2022
$18.84M
Aug 1, 2023
Q1
2023
Mar 31, 2022
$18.84M
May 9, 2023
Q3
2022
Sep 30, 2021
$14.41M
Nov 1, 2022
Q2
2022
Jun 30, 2021
$40.66M
Aug 2, 2022
Q1
2022
Mar 31, 2021
$7.98M
May 3, 2022
Q3
2021
Sep 30, 2020
$3.83M
Nov 2, 2021
Q2
2021
Jun 30, 2020
$212.24M
Aug 3, 2021
Q1
2021
Mar 31, 2020
$1.84M
May 4, 2021
Q3
2020
Sep 30, 2019
$981.0K
Nov 2, 2020
Q2
2020
Jun 30, 2019
$982.0K
Aug 10, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($31.33M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($12.73M)
Aug 13, 2025
Q3
2025
Jun 30, 2025
($12.73M)
Nov 6, 2025
Q3
2025
Mar 31, 2025
($40.46M)
Nov 6, 2025
Q1
2025
Mar 31, 2025
($40.46M)
May 8, 2025
Q2
2025
Mar 31, 2025
($40.46M)
Aug 13, 2025
Q3
2025
Sep 30, 2024
($29.52M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($61.93M)
Aug 13, 2025
Q3
2025
Jun 30, 2024
($61.93M)
Nov 6, 2025
Q1
2025
Mar 31, 2024
$61.02M
May 8, 2025
Q2
2025
Mar 31, 2024
$61.02M
Aug 13, 2025
Q3
2025
Mar 31, 2024
$61.02M
Nov 6, 2025
Q3
2024
Sep 30, 2023
($41.25M)
Nov 7, 2024
Q3
2024
Jun 30, 2023
($49.94M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($49.94M)
Aug 12, 2024
Q3
2024
Mar 31, 2023
($61.72M)
Nov 7, 2024
Q1
2024
Mar 31, 2023
($61.72M)
May 7, 2024
Q2
2024
Mar 31, 2023
($61.72M)
Aug 12, 2024
Q3
2023
Sep 30, 2022
($55.12M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($66.32M)
Aug 1, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($9.96M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
$7.10M
Aug 13, 2025
Q1
2025
Mar 31, 2025
($22.10M)
May 8, 2025
Q3
2025
Sep 30, 2024
($16.03M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
$2.58M
Aug 13, 2025
Q1
2025
Mar 31, 2024
$72.27M
May 8, 2025
Q3
2024
Sep 30, 2023
($27.53M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($37.06M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($48.61M)
May 7, 2024
Q3
2023
Sep 30, 2022
($41.62M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($52.38M)
Aug 1, 2023
Q1
2023
Mar 31, 2022
($42.99M)
May 9, 2023
Q3
2022
Sep 30, 2021
($55.75M)
Nov 1, 2022
Q2
2022
Jun 30, 2021
($32.53M)
Aug 2, 2022
Q1
2022
Mar 31, 2021
($82.82M)
May 3, 2022
Q3
2021
Sep 30, 2020
($80.55M)
Nov 2, 2021
Q2
2021
Jun 30, 2020
$129.17M
Aug 3, 2021
Q1
2021
Mar 31, 2020
($74.45M)
May 4, 2021
Q3
2020
Sep 30, 2019
($65.77M)
Nov 2, 2020
Q2
2020
Jun 30, 2019
($55.30M)
Aug 10, 2020